Publication: 1,2,3-TRIAZOLE SCAFFOLD IN RECENT MEDICINAL APPLICATIONS: SYNTHESIS AND ANTICANCER POTENTIALS
2
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
3855414
Rights Holder(s)
Scopus
Bibliographic Citation
Heterocycles. Vol 105, No.1 (2022), p.147-178
Suggested Citation
Choomuenwai V., Leechaisit R., Pingaew R., Prachayasittikul V., Prachayasittikul S., Prachayasittikul V. 1,2,3-TRIAZOLE SCAFFOLD IN RECENT MEDICINAL APPLICATIONS: SYNTHESIS AND ANTICANCER POTENTIALS. Heterocycles. Vol 105, No.1 (2022), p.147-178. doi:10.3987/REV-22-SR(R)4 Retrieved from: https://hdl.handle.net/20.500.14740/9261
Abstract
Cancer is one of commonly concerned health problems globally and its management is challenging. Besides an availability of diverse classes of anticancer agents, the existing drugs are noted for their limitations such as considerable toxicities, low potency and responsiveness, drug resistance, and others. 1,2,3-Triazole is an attractive heterocyclic scaffold possessing considerable characteristics and is presented in many pharmacologically active molecules. Accordingly, attention has been given to this scaffold in the recent years, especially, in an area of anticancer drug development. In this review, a collection of recently reported triazole based anticancer agents are discussed along with their synthetic methods, proposed molecular targets, and mechanisms of actions. A summary of other recently reported biological activities is also provided. In overview, recent studies suggested that the 1,2,3-triazole based compounds could elicit their anticancer effects against several cancer cell lines via an inhibition of cancer cell growth, an induction of apoptosis, an inhibition of involved enzymes such as aromatase, kinases, and others. Some interesting results from computational studies also discussed relating to the predictions of possible molecular targets. In summary, it is suggested that the 1,2,3-triazole serves as a potential scaffold with noteworthy opportunity for future development of novel anticancer agents to cope with current challenging issues in cancer management. © 2022 The Japan Institute of Heterocyclic Chemistry.